ECE2013 Poster Presentations Endocrine tumours and neoplasia (66 abstracts)
Six-years experience in the treatment of the neuroendocrine tumors with the use of peptide receptor radionuclide therapy (PRRT)
Anna Sowa-Staszczak 1 , Agnieszka Stefanska 1 , Monika Tomaszuk 1 , Aleksandra Gilis-Januszewska 1 , Dorota Pach 1 , Renata Mikolajczak 2 & Alicja Hubalewska-Dydejczyk 1
1Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland; 2Radioisotope Center POLATOM, National Centre for Nuclear Research, Otwock, Poland.
Introduction: The aim of this study was to assess the efficacy of peptide receptor radionuclide therapy (PRRT) with the use of 90Y-DOTATATE and the survival rate of patients with disseminated or non-operable neuroendocrine tumors (NETs).
Methods: In the time period from June 2006 to October 2012, 70 patients were treated with PRRT in our department. The 90Y-DOTATATE therapeutic activity was calculated per total body surface area up to a total of 7.4 GBq/m2 administrated in three to five cycles, repeated every 4–9 weeks. Before and after the therapy, blood tests for hematology, kidney and liver function were performed. After PRRT, patients have been further treated with cold long acting somatostatin analogues (Sandostatin LAR) to the progression of the disease.
Results: Out of 70 90Y-DOTATATE treated patients, 22 died after completing the therapy, among them two due to myocardial infarction. After 12-month follow-up, stabilization of the disease was observed in 63%, partial remission in 25%, and progression in 12% in this group of patients. The progression-free survival (PFS) was found to be 41.27 months and the event-free survival (EFS) 37.73 months. The median overall survival (OS) was not reached. During follow-up, transient decrease in PLT, WBC and hemoglobin values was observed. A increase in creatinine level and decrease in GFR values over observation period were found, but these were clinically insignificant symptoms of transient nephrotoxicity.
Summary: Long-term patients benefit in the form of long survival rate, symptomatic relief and tumor mass reduction after 90Y-DOTATATE therapy was observed. PRRT is safety method and may extend the survival of disseminated patients with NETs.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more